(Reuters) – Eli Lilly and Co on Thursday entered into an agreement with Amgen Inc to increase the supply capacity of the drugmaker’s experimental COVID-19 antibody treatments.
Through the collaboration, the two companies will have the ability to scale up production should one or more of Lilly’s antibody therapies prove successful in clinical testing and receive regulatory approval, the companies said in a statement.
(Reporting by Manas Mishra in Bengaluru; Editing by Maju Samuel)
